Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia

  title={Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia},
  author={Stacey L. House and Craig S. Bolte and Ming Zhou and Thomas C. Doetschman and Raisa Klevitsky and Gilbert Newman and Jo El J. Schultz},
  journal={Circulation: Journal of the American Heart Association},
Background—Preconditioning the heart before an ischemic insult has been shown to protect against contractile dysfunction, arrhythmias, and infarction. Pharmacological studies have suggested that fibroblast growth factor-2 (FGF2) is involved in cardioprotection. However, because of the number of FGFs expressed in the heart and the promiscuity of FGF ligand-receptor interactions, the specific role of FGF2 during ischemia-reperfusion injury remains unclear. Methods and Results—FGF2-deficient (Fgf2… 

Figures and Tables from this paper

The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2.
FGF2-induced cardioprotection is mediated via a PKC-dependent pathway and that the PKC and MAPK signaling cascades are integrally connected downstream of FGF2, according to Western blot analysis and confocal immunofluorescent microscopy.
Fibroblast growth factor 2 is an essential cardioprotective factor in a closed‐chest model of cardiac ischemia‐reperfusion injury
Data reveal both acute cardioprotective and a longer term proangiogenic potential of endogenous FGF2 in a clinically relevant, in vivo, closed‐chest regional cardiac IR injury model that mimics acute myocardial infarction.
Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade.
Our laboratory showed previously that cardiac-specific overexpression of FGF-2 [FGF-2 transgenic (Tg)] results in increased recovery of contractile function and decreased infarct size after
The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling.
Basic Fibroblast Growth Factor Attenuates Injury in Myocardial Infarction by Enhancing Hypoxia-Inducible Factor-1 Alpha Accumulation
BFGF attenuates myocardial injury by inhibiting apoptosis and promoting angiogenesis via a novel HIF-1α-mediated mechanism and a potential utility of bFGF in protecting against myocardia infarction is indicated.
FGF-2 and FGF-16 Protect Isolated Perfused Mouse Hearts from Acute Doxorubicin-Induced Contractile Dysfunction
FGF-2 and FGF-16 increase resistance to acute doxorubicin-induced cardiac dysfunction, and protein kinase C activation is implicated in this response.
Protection by endogenous FGF-2 against isoproterenol-induced cardiac dysfunction is attenuated by cyclosporine A
TDI values in the presence of chronic FGF-2 overexpression are prognostic of an improved cardiac outcome and protection from isoproterenol induced cardiac dysfunction in vivo, and suggest that cyclosporine A-sensitive infiltrating cell population(s) may contribute to the sustained beneficial effect of F GF-2 in vivo.
Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase.
Echocardiography reveals significantly decreased fractional shortening in isoproterenol-treated FGF2 transgenic mice but not in Fgf2 knockout mice suggesting that FGF 2 mediates the maladaptive cardiac dysfunction seen in cardiac hypertrophy induced by isoprotserenol.
Low molecular weight fibroblast growth factor-2 signals via protein kinase C and myofibrillar proteins to protect against postischemic cardiac dysfunction.
Evidence indicates that both PKC α and PKCε play a role in LMW FGF2-mediated protection from cardiac dysfunction and that PKCα signaling to the contractile apparatus is a key step in the mechanism of LMW PKC- mediated protection against myocardial dysfunction.


Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C.
Investigation of the effect of fibroblast growth factor (FGF)-2 on myocardial resistance to injury when administered after the onset of ischemia, in vivo and ex vivo, and the role of FGF-2 receptors and protein kinase C (PKC) finds protection from acute and chronic cardiac dysfunction and damage is provided.
Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts.
FGF-2 overexpression causes augmentation of signal transduction pathways and increased resistance to ischemic injury, and stimulation of endogenous FGF- 2 expression offers a potential mechanism to enhance cardioprotection.
Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury
BFGF-induced increases in cardiac resistance to, and improved functional recovery from, ischemia-reperfusion injury indicate that bFGF may have clinical applications in the treatment of ischemic heart disease.
Fibroblast growth factor-2 mediates pressure-induced hypertrophic response.
Comparison of alpha- and beta-cardiac myosin heavy chain mRNA and protein levels in NC and AC Fgf2(+/+) and FgF2(-/-) mice indicates that myos in heavy chain composition depends on hemodynamic stress rather than on FGF2 or hypertrophy, and that isoform switching is transcriptionally, not posttranscriptionally, regulated.
Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts.
It is concluded that basic FGF attenuates myocardial stunning independent of alterations in Ca(i)(2+) by stimulating NO production via an NOS2-dependent pathway.
Targeted disruption of the Fgf2 gene does not affect vascular growth in the mouse ischemic hindlimb.
It is demonstrated that endogenous FGF-2 is not required for revascularization in the setting of peripheral ischemia, and vascular adaptation, including both angiogenesis and arteriogenesis, was not affected by the absence of F GF-2 in this model.
Negative Inotropic Effect of Basic Fibroblast Growth Factor on Adult Rat Cardiac Myocyte
The pretreatment of myocytes with a neutralizing anti-bFGF antibody abolished the negative inotropic effects of bFGF and indicated that bF GF-induced negative inotropism was considered to be specific for this growth factor.
Negative inotropic effect of basic fibroblast growth factor on adult rat cardiac myocyte.
BFGF, primarily a potent growth promoter, produced acute negative inotropic effects in the adult cardiac myocyte that could have resulted from alterations in intracellular Ca2+ homeostasis and may contribute to myocardial dysfunction associated with ischemia-reperfusion injury and heart transplant rejection.
Longitudinal changes in myocardial basic fibroblast growth factor (FGF-2) activity following coronary artery ligation in the dog.
Coronary collateral flow did not change between 5 min and 2 h following coronary ligation, but was significantly increased at later time points, and the ischemic/normal myocardial basic fibroblast growth factor mitogenic activity ratio in the peripheral isChemic tissue was increased after 2 h of ischemia.